AstraZeneca shares results from phase 3 trial of datopotamab deruxtecan for NSCLC
July 3, 2023Medical Communications AstraZeneca, NSCLC, Oncology, clinical trial, datopotamab deruxtecan
AstraZeneca has announced results from its TROPION-Lung01 phase 3 trial for its TROP2-directed antibody drug conjugate, developed in collaboration with …
Josef Penninger appointed as new scientific director of Helmholtz Centre for Infection Research
July 3, 2023Business Services Helmholtz Centre for Infection Research, Josef Penninger, appointment, scientific director
The Helmholtz Centre for Infection Research (HZI), Germany, has appointed Professor Josef Penninger as scientific director. Penninger has previously worked …
Kevin Hawkins appointed as Reacta’s head of regulatory affairs
July 3, 2023Business Services Kevin Hawkins, Reacta, appointment, head of regulatory affairs
Reacta Healthcare, an early-stage food allergy diagnostic company, has announced the appointment of Kevin Hawkins as head of regulatory affairs. …
FDA approves BioMarin’s Roctavian for adults with severe haemophilia A
June 30, 2023Medical Communications BioMarin, FDA, Haematology, Roctavian, haemophilia
Global biotechnology company BioMarin Pharmaceuticals has announced that the US Food and Drug Administration (FDA) has approved Roctavian (valoctocogene roxaparvocec-rvox) …
Eli Lilly to acquire Sigilon Therapeutics
June 30, 2023Business Services Chronic Diseases, Eli Lilly, Sigilon, acquisition
Eli Lilly and Sigilon Therapeutics have announced a definitive agreement for Lilly’s acquisition of Sigilon, a biopharmaceutical company focusing on …
First cellular therapy for patients with type 1 diabetes approved by FDA
June 29, 2023Medical Communications Diabetes, FDA, Lantidra, Type 1 diabetes, diabetes
The US Food and Drug Administration (FDA) has announced that it has approved Lantidra, the first allogeneic (donor) pancreatic islet …
Astellas establishes open innovation hub for tumour microenvironment research
June 29, 2023Research and Development Astellas Pharma, Mitsui Fudosan, Oncology, open innovation hub, tumour microenvironment
Astellas Pharma and Mitsui Fudosan have announced that Astellas plans to establish a tumour microenvironment (TME) open innovation hub, intended …
Anavex Life Sciences and Partex NV Group announce AI-based strategic partnership to enhance patient experience
June 28, 2023Research and Development AI, Anavex Life Sciences, Partex NV Group, Pharmacy, patient experience
US-based clinical-stage biopharmaceutical company Anavex Life Sciences and German digital pharma platform Partex NV Group have announced a strategic partnership …
Microba commences phase 1 clinical trial for IBD drug
June 28, 2023Medical Communications Biotherapeutic, Gastrointestinal tract, Microba, clinical trials, ibd
Australian precision microbiome company Microba has announced that the first participants in its phase 1 inflammatory bowel disease (IBD) clinical …
Astellas Pharma shares positive results from phase 3b trial of Fezolinetant for menopause symptoms
June 28, 2023Medical Communications Astellas Pharma, Pharmacy, clinical trial, fezolinetant, menopause
Astellas Pharma has announced positive topline results from the phase 3b DAYLIGHT clinical trial for fezolinetant, its investigational oral, nonhormonal …
Bristol Myers Squibb’s Sotyktu recommended for NHS use for adult patients with psoriasis
June 28, 2023Medical Communications Dermatology, NHS, Sotyktu, bristol myers squibb, psoriasis
Bristol Myers Squibb (BMS) has announced that the National Institute for Health and Care Excellence (NICE) has recommended Sotyktu (deucravacitinib) …
UK nonprofit National Cancer Research Institute to close
June 27, 2023Medical Communications Cancer, NCRI, National Cancer Research Institute, Oncology, oncology
The National Cancer Research Institute (NCRI) has announced that it is closing after 22 years of advancing cancer research. Established …
GSK receives FDA Fast Track designation for novel gonorrhoea vaccine
June 27, 2023Research and Development FDA, GSK, Infections and infestations, Vaccine, fast track designation, gonorrhoea
GSK has announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for its investigational vaccine …
AstraZeneca’s Xigduo XR approved in China for adults with type-2 diabetes
June 27, 2023Medical Communications AstraZeneca, China, Diabetes, Xigduo XR, diabetes
AstraZeneca has announced that its Xigduo XR (dapagliflozin and metformin hydrochloride extended-release), a once-daily fixed-dose combination, has now been approved …
Verona Pharma submits FDA New Drug Application for COPD treatment
June 27, 2023Research and Development COPD, Cardiology, FDA, ensifentrine, new drug application, verona pharma
UK-based Verona Pharma has announced that it has submitted a New Drug Application (NDA) to the US Food and Drug …
Sanofi shares data about new drug for haemophilia A in paediatric patients
June 26, 2023Research and Development Haematology, Sanofi, clinical trial, haemophilia a
Sanofi has shared new data from the phase 3 XTEND-Kids study which assessed Altuviiio (Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein) …
FDA approves Pfizer’s Litfulo for patients with severe alopecia areata
June 26, 2023Medical Communications FDA, Litfulo, Pfizer, Pharmacy, alopecia, alopecia areata
Pfizer has announced that the US Food and Drug Administration (FDA) has approved its Litfulo (ritlecitinib) for patients over the …
AstraZeneca’s Soliris given EU CHMP recommendation for marketing authorisation
June 26, 2023Medical Communications AstraZeneca, CHMP, EMA, Immunology, soliris
UK-based biopharmaceutical company AstraZeneca has announced that the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) …
CHMP gives positive opinion recommending authorisation to GSK’s CKD drug
June 26, 2023Medical Communications CKD, EMA, Nephrology
Global biopharmaceutical company GSK has announced that the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) …
Cartesian Therapeutics announces successful trial of RNA cell therapy in autoimmunity
June 23, 2023Research and Development Cartesian Therapeutics, Neurology, RNA, autoimmune, neurology
Clinical stage biotechnology company, Cartesian Therapeutics, has announced results from its clinical trial using RNA CAR T (rCAR T) therapy …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
